A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Trial Profile

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Tralokinumab (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 08 Aug 2017 Primary endpoint has not been met (Change from Baseline in Percent-Predicted Forced Vital Capacity at Week 52), according to results published in the American Journal of Respiratory and Critical Care Medicine.
    • 08 Aug 2017 Results assessing efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis published in the American Journal of Respiratory and Critical Care Medicine.
    • 04 Feb 2016 According to an AstraZeneca media release, status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top